GlaxoSmithKline and Theravance submitted their experimental once-daily UMEC/VI for FDA approval to treat chronic obstructive pulmonary disease. The drug, which would be sold as Anoro Ellipta in the U.S. if approved, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist.

Related Summaries